# Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

> **NCT01631071** · NA · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 110 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Virosomal influenza vaccine

## Key facts

- **NCT ID:** NCT01631071
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2013-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01631071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01631071, "Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01631071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*